Is cisplatin still the best platinum compound in non-small-cell lung cancer?

Annals of Oncology

Volumn 13, Issue 10, 2002, Pages 1515-1517

  Soria, J C ^a   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PACLITAXEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036810141     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf331     Document Type: Editorial

References (25)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Guarino AM, Miller DS, Arnold TS et al. Platinate toxicity: past, present and prospects. Cancer Treat Rep 1979; 63: 1475-1483.
3. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with adavanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
4. Marino P, Pamapallona S, Preatoni A, Cantoni A, Invernezzi F. Chemotherapy versus best supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
5. Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
6. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
7. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-1100.
8. Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in control of cisplatin induced emesis. N Engl J Med 1990; 322: 846-848.
9. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1989; 25: 1-9.
10. Shyr Y, Choy H, Cmelak A et al. Pattern of practice survey: non-small cell lung cancer in the US. Proc Am Soc Clin Oncol 1998; 17: 463a (Abstr 1778).
11. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 1539-1549.
12. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
13. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
14. Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology 1997; 11 (Suppl 2): 1-13.
15. Georgoulias V, Papadakis E, Alexopoulous A et al. Platinum-based and non-platinum based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.
16. Rodriguez J, Pawel A, Pluzanska A et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20: 314a (Abstr 1252).
17. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 13-21.
18. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cispatin and carboplatin. J Clin Oncol 1999; 17: 409-422.
19. Bokemeyer C, Kohrmann O, Tischler J et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good-risk metastatic non-seminatous germ cell tumors. Ann Oncol 1996; 7: 1015-1021.
20. De Andres L, Brunet J, Lopez-Pausa A et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995; 13: 1493-1500.
21. Kelsen D, Atiq OT. Therapy of upper gastrointestinal tract cancers. Curr Probl Cancer 1991; 15: 237-294.
22. Kelly K, Crowley J, Bunn PA et al. A randomized phase III trial of paclitaxel plus cisplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
23. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
24. Yuen A, Halsey J, Fisher G et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20: 309a (Abstr 1234).
25. Perez-Soler R, Chachoua A, Huberman M et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 310a (Abstr 1235).